Patients with metastatic breast cancer using bevacizumab as a treatment: is there still a role for it?
about
Neoadjuvant Bevacizumab plus Chemotherapy versus Chemotherapy Alone to Treat Non-Metastatic Breast Cancer: A Meta-Analysis of Randomised Controlled TrialsThe addition of bevacizumab to standard chemotherapy in breast cancer: which patient benefits the most?Bevacizumab specifically decreases elevated levels of circulating KIT+CD11b+ cells and IL-10 in metastatic breast cancer patients.Controlling escape from angiogenesis inhibitors.Obesity promotes resistance to anti-VEGF therapy in breast cancer by up-regulating IL-6 and potentially FGF-2.
P2860
Patients with metastatic breast cancer using bevacizumab as a treatment: is there still a role for it?
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Patients with metastatic breas ...... is there still a role for it?
@en
Patients with metastatic breas ...... is there still a role for it?
@nl
type
label
Patients with metastatic breas ...... is there still a role for it?
@en
Patients with metastatic breas ...... is there still a role for it?
@nl
prefLabel
Patients with metastatic breas ...... is there still a role for it?
@en
Patients with metastatic breas ...... is there still a role for it?
@nl
P2860
P1476
Patients with metastatic breas ...... is there still a role for it?
@en
P2093
Ana Elisa Lohmann
Stephen Chia
P2860
P2888
P304
P356
10.1007/S11864-012-0181-9
P577
2012-06-01T00:00:00Z